Patents Assigned to Novo Nordisk A/S
  • Patent number: 10850041
    Abstract: A drug delivery device is provided comprising or adapted to receive a cartridge with an axially displaceable piston. The drug delivery device comprises a housing, a stationary capacitive sensor assembly, and a moveable indicator element comprising a surface with a code pattern detectable by the stationary capacitive sensor. The code pattern is formed from conductive markings printed onto the surface. The capacitive sensor is formed on a flexible sheet mounted at least in part to the exterior of the housing.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: December 1, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Andre Larsen, Henrik Riehm Soerensen
  • Patent number: 10835602
    Abstract: The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 17, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Parshad, Dorthe Kot Engelund
  • Patent number: 10835683
    Abstract: A drug delivery system comprises an indicator element and a sensor system. The indicator element is arranged to rotate relative to a reference component and corresponding to a reference axis and comprises a plurality of dipole magnets. The sensor system comprises a plurality of magnetometers arranged non-rotational relative to the reference component and adapted to determine continuous magnetic field values from the plurality of dipole magnets, as well as processor means configured to determine on the basis of measured values from the plurality of magnetometers a rotational position and/or a rotational movement of the indicator element.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: November 17, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Nikolaj Eusebius Jakobsen, Preben Mikael Nielsen, Nikolaj Frogner Krusell, Laurits Hoejgaard Olesen
  • Patent number: 10828427
    Abstract: The invention relates to an injection system or a needle assembly in which a needle cannula secured to an injection device is shielded by a axially movable needle shield. Should the needle cannula be exposed to a force above a predetermined value e.g. if a user drops the injection device onto a hard surface, a locking mechanism will automatically lock and block further movement of the axially movable needle shield and thus render the injection device unusable.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: November 10, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Bjoern Gullak Larsen, Christoffer Busk Stormoen, Kurt Solgaard, Thomas Olund Christensen
  • Patent number: 10822385
    Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 3, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
  • Patent number: 10815299
    Abstract: A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 27, 2020
    Assignee: NOVO NORDISK A/S
    Inventors: Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Rozana Sten, Lene Hjorth Alifrangis, Rune Viig Overgaard
  • Patent number: 10814067
    Abstract: A drug delivery device is provided comprising or adapted to receive a cartridge with an axially displaceable piston. The drug delivery device comprises a housing, a stationary capacitive sensor assembly, and a moveable indicator element comprising a surface with a code pattern detectable by the stationary capacitive sensor. The code pattern is formed from conductive markings printed onto the surface. The capacitive sensor is formed on a flexible sheet mounted at least in part to the exterior of the housing.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 27, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Andre Larsen, Henrik Riehm Soerensen
  • Patent number: 10806866
    Abstract: The present invention provides a drug delivery device (1) comprising a drug delivery unit (10) comprising a dose expelling mechanism operable to expel a dose of drug from a drug reservoir (11), a cap (20) configured for dismountable mounting over a portion of the drug delivery unit (10), the cap (20) comprising a cavity (25, 26) for reception of the portion of the drug delivery unit (10), a seal (40) adapted to provide a sealing in an interface between the cap (20) and the drug delivery unit (10), a sensor system (30) configured to monitor internal pressure in the cavity (25, 26) and to register an event in response to sensing a change in the internal pressure which numerically exceeds a specified threshold level over a period of less than 5 seconds, and energy means (50) for powering the sensor system (30).
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 20, 2020
    Assignee: Novo Nordisk A/S
    Inventor: Ulrik Detlef Raedisch Poulsen
  • Patent number: 10799634
    Abstract: A method of manufacturing one of a range of autoinjectors having cartridges (600, 600?, 600?) with different preset fill volumes, the method comprising the steps of: a) providing a front body assembly (100b, 100c, 100c?, 100c?), b) providing a cartridge (600, 600?, 600?) of given fill volume, c) providing a rear body assembly (100a) comprising a spring-driven drive ram assembly (310, 320) configured to drive the piston of a held cartridge (600, 600?, 600?), d) providing a ram spacer member (400, 400?, 400?), the ram spacer member defining a spacing geometry of length dimension (X1?, X1?, X1??, XS?, XS?, XS??, XR?, XR?, XR??) selected according to the fill volume of the cartridge (600, 600?, 600?), and e) assembling a front body assembly (100b, 100c, 100c?, 100c?), the cartridge (600, 600?, 600?), the ram spacer member (400, 400?, 400?) and the rear body assembly (100a) so that the ram spacer member (400, 400?, 400?) is arranged axially between the drive ram assembly (310, 320) of the rear body assembly (100a)
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: October 13, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Mads Schenstroem Stefansen, Soeren Kjellerup Hansen, Klaus Bendix
  • Patent number: 10799644
    Abstract: The invention relates to a medical injection device having a polymeric housing or housing parts. The housing comprises a moulded outer housing element and a moulded elongated tubular inner housing element. The elongated tubular inner housing element is formed as one unitary element and carries a pointer and one or more projections in predetermined and correlated positions. The pointer points to indicia on a scale drum and the projections engage the scale drum. The outer housing element is moulded over the elongated tubular inner housing element in a 2K moulding to form one single housing component.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 13, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Ken Hansen, Imran Ghulam, Jesper Bach Noergaard, Claus Urup Gjoedesen, Asger Meng Larsen
  • Publication number: 20200305788
    Abstract: Systems and methods are provided for adjusting a standing insulin medicament dosage regimen for a subject. Fasting events are Device for adjusting a standing insulin regimen identified using autonomous timestamped glucose measurements of the subject in a first data set. A second data set, from one or more insulin pens used to apply the standing regimen, comprises records, each record comprising a timestamped event specifying an amount of injected insulin medicament. Each fasting event is characterized as adherent or nonadherent. A fasting event is adherent when the second data set includes one or more records that temporally and quantitatively establish adherence with the standing regimen during the fasting event. Conversely, a fasting event is nonadherent when the second data set fails to temporally and quantitatively establish adherence with the standing regimen.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 1, 2020
    Applicant: Novo Nordisk A/S
    Inventors: Henrik Bengtsson, Tinna Bjoerk Aradottir
  • Publication number: 20200308274
    Abstract: The present invention relates to specific antibodies and use thereof, such as for identifying and/or quantifying liraglutide fibrils and/or semaglutide fibrils.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 1, 2020
    Applicants: Novo Nordisk A/S, Regents of the University of Michigan, Regents of the University of Michigan
    Inventors: Peter Matthew Tessier, Samuel D. Stimple, Arne Staby
  • Patent number: 10786628
    Abstract: The present invention provides a piston washer (1, 51) for a drug delivery device, the piston washer (1, 51) comprising a central portion (2, 72) arranged about a centre axis, a peripheral portion (3, 73), and an axially pliable structure (8, 78) connecting the central portion (2, 72) and the peripheral portion (3, 73). The axially pliable structure (8, 78) is preconfigured to undergo permanent deformation in response to a difference between a first resultant force acting on the peripheral portion (3, 73) and a second resultant force acting on the central portion (2, 72) exceeding a threshold level.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 29, 2020
    Assignee: Novo Nordisk A/S
    Inventor: Nikolaj Eusebius Jacobsen
  • Patent number: 10773029
    Abstract: The invention relates to a prefilled injection pen for apportioning multiple set doses of a liquid drug. The injection pen comprises a housing assembly with a removable cap rotatable coupled to the housing assembly such that the user has to rotate the removable cap upon mounting and dismounting the removable cap. Rotation of the removable cap initiates a process in which the proximal end of a needle cannula is first inserted into a cartridge permanently embedded in the housing assembly and thereafter moves the cartridge proximally to thereby pump a predetermined amount of the preservative containing liquid drug from the cartridge and into a cleaning chamber carried by an axially movable shield. The needle cannula is mounted in a needle hub which is arranged to follow rotation of the removable cap and guided helically in relation to the housing assembly such that the needle hub is moved proximally upon rotation of the removable cap.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: September 15, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Simon Munch Pedersen, Lars Eilertsen, Morten Revsgaard Frederiksen, Ruben Archilla, Mattias Ingerslev, Bo Radmer, Rasmus Kann Jensen, Kurt Solgaard
  • Publication number: 20200261595
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 20, 2020
    Applicant: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • Publication number: 20200246545
    Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject) such as a liquid pharmaceutical agent.
    Type: Application
    Filed: January 31, 2020
    Publication date: August 6, 2020
    Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital Inc., Novo Nordisk A/S
    Inventors: Robert S. Langer, Carlo Giovanni Traverso, Alex G. Abramson, Morten Revsgaard Frederiksen, Mikkel Oliver Jespersen, Brian Mouridsen, Jesper Windum, Mette Poulsen, Brian Jensen, Jorrit Jeroen Water, Mikkel Wennemoes Hvitfeld Ley, Xiaoya Lu
  • Patent number: 10722656
    Abstract: The invention relates to a piston rod drive arrangement for an injection device used for self-administration of a plurality of individually set doses. The drive arrangement is made from a first element (10) mating the non-circular cross-section (3) of a piston rod (1) and a second element (20) having an inner thread (21) mating the outer thread of the piston rod. Whenever the first element (10) and the second element (20) are rotated in relation to each other the piston rod (1) is moved in an axial direction. In order to minimise the play in the threaded connection a resilient element (23) is proved to apply a force to the piston rod (1) in a longitudinal direction.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: July 28, 2020
    Assignee: Novo Nordisk A/S
    Inventor: Simon Munch Pedersen
  • Patent number: 10717784
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 21, 2020
    Assignee: NOVO NORDISK A/S
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • Patent number: 10709782
    Abstract: The invention relates to stable and low viscous (<50 cP) protein containing compositions, in particular, but not exclusively stable antibody containing compositions and to the use of said stable proteins in therapy, in particular for the subcutaneous delivery of said stable protein.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 14, 2020
    Assignee: NOVO NORDISK A/S
    Inventor: Henrik Parshad
  • Publication number: 20200206428
    Abstract: The invention provides a pen-type injection device (1) with a piston rod brake mechanism for improving the determination of an expelled dose.
    Type: Application
    Filed: May 7, 2018
    Publication date: July 2, 2020
    Applicant: Novo Nordisk A/S
    Inventors: Nikolaj Eusebius Jakobsen, Steffen Hansen